MONDAL, Sweden -
April 18, 2013 -
PRLog -- Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be exhibiting its revolutionary
in-situ transfection technology platforms on booth #1178 at the Experimental Biology (http://experimentalbiology.org/
EB/pages/default.aspx?
splashpage=1)
conference (20-24 April, Boston, US). Cellectricon will also present two posters on April 24, focusing on high performance
in-situ transfection. The poster “Transfection of primary and iPSC-derived cells by capillary electroporation”
(LB162) explores how Cellectricon’
s novel electroporation Cellaxess® ACE (http://www.cellectricon.com/
products-and-
services/cellaxess-
ace/) system is ideal for
in-situ transfection of any adherent cell type. Minimal cell processing and low voltages ensure excellent viability and completely retained morphology, in any cell culture format.
For
in-situ transfection applications on a larger scale, the poster “High throughput
in-situ transfection of primary and iPSC-derived cells” (LB163) details how the novel electroporation platform Cellaxess® Elektra (
http://www.cellectricon.com/products-and-services/cellaxe...) is optimized for
in-vitro transfection of primary and iPSC-derived cells, directly into 384-well plates. With virtually no impact on cell viability or morphology, this system is ideal for screening applications such as cDNA and RNAi. The presentations will commence from 12:15 to 13:30, and posters will be available for viewing throughout the day.
For more information on the Cellaxess ACE, Cellaxess Elektra and Cellectricon’
s Discovery Services, visit
www.cellectricon.com
Account Phone Number